Archives
- o2h Ventures ‘Knowledge Intensive Human Health EIS Fund’ invests into BiVictriX Therapeutics 5 August, 2021
- Digital brain biomarker company Monument Therapeutics raises £2.6 million 20 July, 2021
- o2h Ventures backed Arecor Granted Key US Patent 14 May, 2021
- o2h Ventures backed Small Pharma Raises Cash to Fund Reverse Takeover on Toronto Stock Exchange 12 May, 2021
- o2h Ventures backed In4Derm Announces a Strategic Partnership with a Nasdaq listed biotech with a >$200m Option License Agreement 11 May, 2021
- Sunil Shah, CEO of o2h ventures, wins the Cambridge Independent Science and Technology Awards as CEO of the Year 16 April, 2021
- University of Sussex and o2h Ventures Announce Creation and Investment in Stingray Bio, a Company for New Oncology Drugs Targeting the LMTK3 Kinase Pathway 8 April, 2021
- The o2h human health S/EIS flagship fund – Fully Deployed 1 April, 2021
- o2h Ventures invests into SomaServe’s successful Series A funding round 31 March, 2021
invest in the growth potential of UK life science & AI